Skip to main content
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1979;7(Suppl 1):113S–118S. doi: 10.1111/j.1365-2125.1979.tb04676.x

Evaluation of the effects of clobazam, a 1,5 benzodiazepine, on mood and psychomotor performance in clinically anxious patients in general practice

M R Salkind, G W Hanks, J T Silverstone
PMCID: PMC1429522  PMID: 35189

Abstract

1 The methodology of clinical trials of anxiolytic drugs carried out in general practice conditions is discussed. Particular problems include: the selection of suitable patients; placebo effects; the influence of non-specific variables such as life-events; and patient compliance.

2 Clobazam, a novel 1,5 benzodiazepine, and diazepam were compared with placebo in a double-blind group comparative trial in general practice, which was designed to avoid as many confounding variables as possible. Anxiety-reducing effects were evaluated and at the same time the effects of the drugs on psychomotor performance were examined.

3 Both clobazam and diazepam produced significant improvements in anxiety ratings on the Hamilton Anxiety Scale and the Morbid Anxiety Inventory, whereas placebo did not.

4 The placebo group demonstrated a significant improvement in performance on a pursuit rotor and digit symbol substitution test (DSST), whereas the diazepam group's performance did not change. The clobazam group showed improvement in both tests, significantly so in the DSST. This suggests that diazepam produces impairment in performance, which had negated the practice effect seen in the placebo group, whereas clobazam did not seem to produce similar impairment.

Full text

PDF
113S

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barzaghi F., Fournex R., Mantegazza P. Pharmacological and toxicological properties of clobazam (1-phenyl-5-methyl-8-chloro-1,2,4,5-tetrahydro-2,4-diketo-3H-1,5-benzodiazepine), a new psychotherapeutic agent. Arzneimittelforschung. 1973 May;23(5):683–686. [PubMed] [Google Scholar]
  2. Borland R. G., Nicholson A. N. Immediate effects on human performance of a 1,5-genzodiazepine (clobazam) compared with the 1,4-benzodiazepines, chlordiazepoxide hydrochloride and diazepam. Br J Clin Pharmacol. 1975 Jun;2(3):215–221. doi: 10.1111/j.1365-2125.1975.tb01578.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. HAMILTON M. The assessment of anxiety states by rating. Br J Med Psychol. 1959;32(1):50–55. doi: 10.1111/j.2044-8341.1959.tb00467.x. [DOI] [PubMed] [Google Scholar]
  4. Hindmarch I. Some aspects of the effects of clobazam on human psychomotor performance. Br J Clin Pharmacol. 1979;7 (Suppl 1):77S–82S. doi: 10.1111/j.1365-2125.1979.tb04669.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Koeppen D. Review of clinical studies on clobazam. Br J Clin Pharmacol. 1979;7 (Suppl 1):139S–150S. doi: 10.1111/j.1365-2125.1979.tb04684.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Salkind M. R. Anxiety neurosis in general practice. Postgrad Med J. 1972 Sep;48(4 Suppl):34–41. [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES